From the 2013 2013 Genitourinary Cancers Symposium: High-Risk Prostate Cancer Treated with Pelvic Radiotherapy and 36 Versus 18 Months of Androgen Blockade

Men who are diagnosed with high risk prostate cancer, meaning they are more likely to develop advanced prostate cancer are usually treated with Radiotherapy (RT) and long term androgen blockade (AB). Currently, we do not know what is the optimal duration of AB. Looking at this problem, the researchers conducted a randomized study to compare [...]

The FDA Has Approved TRELSTAR(R) 22.5 mg, The First 6-Month GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer

Watson Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Trelstar – 22.5 mg (triptorelin pamoate for injectable suspension) at a dosage which will be required only to be administered twice a year. […]

Comparing Intermittent To Continuous Androgen Deprivation For Advanced Prostate Cancer

A recent Finnish study released interim results comparing intermittent androgen deprivation (IAD) to continuous androgen deprivation (CAD) in 856 men. All the men had locally advanced or metastatic prostate cancer and they all were treated at 27 clinics in Finland. The period of study was between 1997 and 2003 and all men were required to [...]

ADT & Radiation

April 14 in the Journal of Clinical Oncology reported that Eric M. Horwitz, M.D., from Fox Chase Cancer Center in Philadelphia, and colleagues treated 1,554 prostate cancer patients with goserelin and flutamide (ADT) before and during radiation therapy. The men were then randomly assigned to receive no further ADT or 24 additional months of ADT. [...]